HeartMate 3支持患者中阿哌沙班血浆水平研究
该回顾性研究纳入34例HeartMate 3患者(4例儿童,30例成人),自2023年6月起启动阿哌沙班抗凝并监测谷浓度,目标调整至超过50ng/ml。总随访3191患者天,无重大凝血事件,发生6次轻微出血(0.69次/患者年),67%发生于联用阿司匹林的双联治疗期间。
要点
- 以谷浓度>50ng/ml为目标调整剂量,随访3191患者天无血栓事件。
- 轻微出血0.69次/患者年,多数发生在与阿司匹林联用时。
- 阿哌沙班峰浓度个体间和个体内变异较大,谷浓度变异较小。
核心结论
- 以谷浓度>50ng/ml为目标调整阿哌沙班剂量,随访3191患者天无血栓事件,无重大出血,仅少数轻微出血且多与联用阿司匹林相关。
研究设计与样本
- 回顾性研究,纳入34例HeartMate 3患者,其中4例儿童(均初次使用)和30例成人(16例初次使用)。
- 自2023年6月起所有新植入患者启用阿哌沙班,住院成人患者从维生素K拮抗剂转换为阿哌沙班。
- 所有患者测量阿哌沙班谷浓度,考虑调整剂量以使谷浓度超过50ng/ml。
主要发现
- 初次使用时,儿童术后中位启动时间为14天(IQR 11-16),成人为11天(IQR 6-13)。
- 总随访3191患者天(其中儿童820患者天),无重大凝血事件。
- 发生6次轻微出血事件,发生率为0.69次/患者年,其中67%发生在与阿司匹林双联治疗期间。
- 14例患者进行了剂量调整;最终剂量下儿童组中位谷浓度73ng/ml(IQR 50-92)、峰浓度179ng/ml(IQR 133-242),成人组中位谷浓度109ng/ml(IQR 83-144)、峰浓度176ng/ml(IQR 134-228)。
- 阿哌沙班峰浓度的个体间和个体内变异较大,而谷浓度变异较小。
关键数值与推荐
- 剂量调整目标为阿哌沙班谷浓度超过50ng/ml。
临床怎么用
- 在HeartMate 3支持患者中可考虑使用阿哌沙班抗凝,并以谷浓度>50ng/ml为目标进行剂量调整。
- 监测谷浓度可能比峰浓度更稳定,联用阿司匹林时需关注出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apixaban is increasingly used instead of vitamin K antagonists (VKAs) for long-term anticoagulation during HeartMate 3 (HM3) support. However, data on its pharmacokinetics in this context is lacking. We present real-world data on apixaban levels and outcomes in adult and pediatric HM3 patients, and evaluate our dosing strategy based on plasma sampling. METHODS: Since June-2023, all new HM3 recipients were initiated on apixaban. Additionally, hospitalized adult HM3 patients were transitioned from VKA to apixaban. Trough apixaban levels were measured in all patients, and dose adjustment was considered to exceed 50ng/ml. RESULTS: This retrospective study includes 34 HM3 patients, 4 pediatric (all primary use) and 30 adult patients (16 primary use). In primary use, apixaban was started at median of 14 (interquartile range [IQR]: 11-16, pediatric) and 11 (IQR: 6-13, adult) days postoperatively. No major coagulopathic events occurred during an overall follow-up of 3,191 patient-days. Six minor bleeding events occurred (0.69 events per patient-year), mostly (67%) during dual therapy with aspirin. Fourteen patients had dose adjustment; median trough and peak levels on final dosage were 73 (IQR: 50-92) and 179 (IQR: 133-242) ng/ml in the pediatric group and 109 (IQR: 83-144) and 176 (IQR: 134-228) ng/ml in the adult cohort, respectively. Inter- and intraindividual variation in apixaban peak levels was considerable, while trough levels showed less variability. CONCLUSIONS: With a dosing strategy to target trough apixaban levels of >50ng/ml, there were no thrombotic events during a follow-up of 3,191 patient-days (of which 820 patient-days in children). We observed no major, and only few non-major bleeds, mainly in patients concomitantly taking aspirin.
引用
- Van Edom CJ, Cools B, Droogné W, et al. Apixaban plasma levels in patients with HeartMate 3 support. J Heart Lung Transplant. 2024. PMID: 39551171. doi:10.1016/j.healun.2024.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。